clinical trial semaglutide New Wegovy finds surprising benefits that go way beyond weight loss Post hoc analysis of SUSTAIN

Semaglutide is eliminated primarily through peptide degradation and glomerular filtration, not hepatic metabolism, which means it does not compete with HRT for liver enzyme systems like cytochrome P450

approved the drug in 2021

Clinical trials show: Wegovy users lost an average of 15% of body weight in 68 weeks Ozempic users lost up to 10% of their weight over a similar period

5.4.1 Non-Invasive Neuromodulation Therapies Axon Therapy This treatment has been approved by the FDA in 2024 for painful DPN, it uses magnetic peripheral nerve stimulation (mPNS) to target damaged nerves

This is a legitimate concern that requires proactive management